BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
95.8%
Operating margin
-104.2%+5647.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +126.3% | +86.3% | +127.4% | – | |
| Gross profit | +120.7% | +86.5% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 6.72 | 2.77 | |
| Debt to equity | – | 1.62 | – | |
| Net debt to EBITDA | – | 0.55× | – | |
| Interest coverage | – | -12.9× | -9.9× | |
| Capex to revenue | – | 91.1% | 0.2% | |
| Diluted shares | – | 118M | 192M |
Where the cash went
Fiscal 2021 to 2025, five years combined
BridgeBio Pharma generated $2.41B from operations and spent $269.68M on capital expenditure, dividends and share buybacks. 8% of that went back into the business.
Generated
$2.41B
Used
$269.68M
Capital expenditure$21.40M8%Dividends$00%Share buybacks$248.28M92%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$445.91M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$445.91M vs –
- Less leverageLong-term debt to assets fell47.6% → –
- Better liquidityCurrent ratio rose4.67 → 2.77
- No dilutionShare count did not rise186M → 192M
- Gross margin improvedGross margin up on the prior year98.25% → 95.82%
- More efficientAsset turnover rose0.41 → 0.55